Founded in San Jose, California, Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on revolutionizing drug delivery through its innovative RaniPill capsule. The company's mission is to transform the administration of biologics by making them orally available, thus improving patient compliance and expanding therapeutic possibilities. Rani Therapeutics' product pipeline includes RT-101 for neuroendocrine tumors and acromegaly, and RT-102 for parathyroid hormone deficiencies.
Notable figures associated with Rani Therapeutics include its founder Mir Imran, a renowned medical device innovator. The company has attracted significant investment from leading venture capital firms and strategic partners. Key achievements include the successful completion of Phase I clinical trials for RT-101, demonstrating the potential of their oral delivery platform. Rani Therapeutics' work has the potential to significantly impact the biotherapeutics market by providing a more convenient and effective method of drug administration.
